NASDAQ:EQ Equillium (EQ) Stock Price, News & Analysis $1.07 -0.05 (-4.46%) (As of 10/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Equillium Stock (NASDAQ:EQ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Equillium alerts:Sign Up Key Stats Today's Range$1.05▼$1.1350-Day Range$0.78▼$1.1352-Week Range$0.45▼$3.25Volume140,142 shsAverage Volume264,635 shsMarket Capitalization$37.72 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewEquillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Read More… [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Equillium Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks42nd Percentile Overall ScoreEQ MarketRank™: Equillium scored higher than 42% of companies evaluated by MarketBeat, and ranked 684th out of 998 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEquillium has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEquillium has only been the subject of 1 research reports in the past 90 days.Read more about Equillium's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Equillium are expected to decrease in the coming year, from ($0.14) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Equillium is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Equillium is -4.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEquillium has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Equillium's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.09% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently increased by 23.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEquillium does not currently pay a dividend.Dividend GrowthEquillium does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.09% of the float of Equillium has been sold short.Short Interest Ratio / Days to CoverEquillium has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Equillium has recently increased by 23.70%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Equillium this week, compared to 1 article on an average week.Search Interest4 people have searched for EQ on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Equillium insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,085.00 in company stock.Percentage Held by Insiders30.30% of the stock of Equillium is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.05% of the stock of Equillium is held by institutions.Read more about Equillium's insider trading history. Receive EQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Equillium and its competitors with MarketBeat's FREE daily newsletter. Email Address EQ Stock News HeadlinesHead-To-Head Survey: InterCure (NASDAQ:INCR) and Equillium (NASDAQ:EQ)October 19 at 1:17 AM | americanbankingnews.comEquillium (NASDAQ:EQ) vs. Moleculin Biotech (NASDAQ:MBRX) Head to Head AnalysisOctober 16, 2024 | americanbankingnews.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.October 22, 2024 | Insiders Exposed (Ad)Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of CancerOctober 7, 2024 | finance.yahoo.comEquillium (NASDAQ:EQ) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEquillium collaborates with Vivtex for oral formulation of autoimmune therapySeptember 17, 2024 | msn.comEquillium to Present at the Stifel Virtual Inflammation & Immunology SummitSeptember 10, 2024 | finance.yahoo.comEquillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceAugust 28, 2024 | finance.yahoo.comSee More Headlines EQ Stock Analysis - Frequently Asked Questions How have EQ shares performed this year? Equillium's stock was trading at $0.7230 at the start of the year. Since then, EQ shares have increased by 48.0% and is now trading at $1.07. View the best growth stocks for 2024 here. How were Equillium's earnings last quarter? Equillium, Inc. (NASDAQ:EQ) announced its earnings results on Thursday, August, 8th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.16. The company earned $13.85 million during the quarter, compared to analysts' expectations of $8.15 million. Equillium had a negative trailing twelve-month return on equity of 36.88% and a negative net margin of 19.51%. When did Equillium IPO? Equillium (EQ) raised $70 million in an IPO on Friday, October 12th 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and Stifel served as the underwriters for the IPO. How do I buy shares of Equillium? Shares of EQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Equillium own? Based on aggregate information from My MarketBeat watchlists, some other companies that Equillium investors own include NVIDIA (NVDA), Meta Platforms (META), Bank of America (BAC), Advanced Micro Devices (AMD), AbbVie (ABBV), Tilray (TLRY) and Carnival Co. & (CCL). Company Calendar Last Earnings8/08/2024Today10/22/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EQ CUSIPN/A CIK1746466 Webequilliumbio.com Phone(858) 240-1200FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,340,000.00 Net Margins-19.51% Pretax Margin-18.31% Return on Equity-36.88% Return on Assets-17.31% Debt Debt-to-Equity RatioN/A Current Ratio2.08 Quick Ratio2.08 Sales & Book Value Annual Sales$42.62 million Price / Sales0.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.72Miscellaneous Outstanding Shares35,255,000Free Float24,691,000Market Cap$38.78 million OptionableNot Optionable Beta1.83 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:EQ) was last updated on 10/22/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredElection rigged? We caught them red-handed…What happens if NOBODY will be elected the next President of the United States on Nov. 5? Not Donald Trump...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | SponsoredFed Quietly Admits Gold is Replacing the DollarA major shift is occurring in the global financial system… The Fed has "quietly admitted" that Gold is repl...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.